AdAlta completes enrolment for AD-214 fibrosis safety trial

Spread the love

–News Direct–

AdAlta Ltd (ASX:1AD) CEO Dr Tim Oldham tells Proactive the company has wrapped up the enrolment of healthy volunteers for its AD-214 Phase 1 extension study, and early indications are that it is well tolerated. The aim of the trial is to evaluate the safety of AD-214, the companys flagship candidate for treating fibrotic diseases including Idiopathic Pulmonary Fibrosis.

Oldham said: We are grateful to all the volunteers that have participated in this Phase 1 extension study.

The data being generated continues to show that AD-214 is well tolerated and is also helping to inform dosing regimens and the broader protocol for our coming Phase 2 study for AD-214.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

[email protected]

View source version on

AdAlta Ltd

comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Graph Daily journalist was involved in the writing and production of this article.

Cloud PR Wire

Cloud PR Wire